🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Organoid atlases developed by Institute of Human Biology ETH Zurich & Helmholtz Munich | @HelmholtzMunich are now part of the Human Cell Atlas —laying the groundwork for precision models & future therapies. Built by global collaboration, powered by AI, designed to accelerate human disease modeling. Find out more

Did you know that mass spectrometry can help tackle disease? Enter a new dimension in mass spectrometry where vitamin D precision analysis can unlock personalized treatment plans for newborns and those in critical care. go.roche.com/msvdx #RocheMassSpec

#MEDIA – We are happy to announce that the US FDA has approved our refillable eye implant for its third indication, diabetic retinopathy (DR) - a leading cause of #VisionLoss in adults with diabetes. roche.com/media/releases… $ROG $RHHBY

#MEDIA – We are pleased to announce new two-year follow-up data at #ASCO25, showing an extended survival benefit with our off-the-shelf bispecific antibody combination, for people with an aggressive form of #lymphoma, after initial relapse. spkl.io/6010fNuCI $RHHBY $ROG

#MEDIA — We are pleased to announce a positive CHMP opinion for our medicine in advanced PIK3CA-mutated, ER-positive, HER2-negative #BreastCancer, an aggressive subtype of breast cancer associated with a poor prognosis. spkl.io/6019fNTNv $ROG $RHHBY

Our world is moving toward faster, personalized diagnostics. Next-generation sequencing (NGS) leads the way by uncovering the genetics of complex diseases. At Roche, we're advancing NGS with our innovative sequencing by expansion (SBX) technology. Learn more:

At Roche, we're committed to combating AMR with scientific collaboration and innovative diagnostics and treatments. We're at the forefront of scientific collaboration to improve patient access to the latest innovations. #AMR #AntibioticResistance #RocheAMR

#MEDIA — New 96-week data shows maintained near-complete suppression of disease activity and no disability progression for up to two years in people with relapsing multiple sclerosis. spkl.io/6014ffUv2 #MultipleSclerosis #ClinicalTrials $ROG $RHHBY

#MEDIA — We are pleased to be presenting new overall survival data at #ASCO25 for our medicine in people with advanced PIK3CA-mutated, HR-positive, HER2-negative #BreastCancer, supporting standard of care potential. spkl.io/6018ffNsm $ROG $RHHBY

#MEDIA We are very encouraged about the Phase III data being presented at #ASCO25 by @Alliance_org in #coloncancer. Huge thanks to Alliance, the investigators and patients taking part in this study. $ROG $RHHBY

#MEDIA – We are pleased our Phase III data at #ASCO25, published in #TheLancet, show survival benefits for people with small cell #lungcancer. SCLC is an aggressive cancer type where more options for disease control are highly needed: spkl.io/6016fAn54 $ROG $RHHBY

Antimicrobial resistance (AMR) is a pressing reality. The WHO projects that AMR could cause up to 10 million deaths annually by 2050 if current trends continue. Let's take action now to ensure life-saving medicines remain effective for future generations.

#MEDIA —We are advancing our investigational anti-alpha-synuclein antibody into Phase III development for early-stage #ParkinsonsDisease spkl.io/6016fC0xi $ROG $RHHBY

Pharma and academia play distinct but complementary roles in driving innovation. In a new nature article, Hans Clevers shares insights on how bridging both worlds can accelerate progress in healthcare. Read more here: spkl.io/6010fhJIC

#MEDIA – We're pleased to share new late-breaking data at #18ICML, showing that our investigational combination treatment could offer people with aggressive #lymphoma a well-tolerated option without traditional chemotherapy. spkl.io/6010fh0JC $RHHBY $ROG

We’re expanding affordable pricing for HPV DNA testing to support critical screening for an additional 50 million women living in LMICsUp. go.roche.com/ccagapx #CervicalCancerElimination #GlobalHealth #HPVTesting #Roche

#MEDIA We’re please to share that Phase I/II data presented at #ISTH2025 show that our investigational bispecific antibody may have the potential to provide haemostatic normalization in people with haemophilia A. spkl.io/6010A6KIA

We're proud to renew our collaboration with The Global Fund to strengthen lab systems and diagnostics services that are essential for equitable access to care. Together, we leverage our expertise, resources and network to maximize our impact in low and middle-income countries.

Next-generation sequencing (NGS) plays an essential role in understanding the genetics of complex diseases. At Roche, we are leading the way with our breakthrough technology, sequencing by expansion (SBX). Discover how SBX is revolutionizing genomics: go.roche.com/xsbxao08

Mass spectrometry has the potential to provide patients with more personalised diagnoses. But do you know what makes this technology a gold standard in clinical diagnostic testing? Select your answer below. #massspectrometry #innovation #diagnostics #RocheMassSpec